Completely Resected Pituitary Macroadenomas Have a Low Risk of Long-Term Radiographic Progression

Background: In 2017, the FDA issued a warning regarding the risk of chronic retention of gadolinium in several body tissues, including brain, following the administration of gadolinium-based contrast agents. This risk is heightened in patients requiring multiple lifetime doses, such as those who have undergone pituitary adenoma surgery. In this study, we assessed the long-term risk of radiographic recurrence of pituitary macroadenomas in an attempt to define patients at low risk for progression, in whom fewer surveillance scans may be warranted.

Methods: The records of all patients undergoing endoscopic endonasal transsphenoidal resection of pituitary macroadenomas between 2007 and 2011 at our institution were reviewed. Only patients with more than 3 years of clinical and radiographic follow-up were included.

Results: 45 patients with at least 3 years of follow-up were identified, 33 of whom had at least 5 years of follow-up. The average age was 53 ± 18 years. Twenty patients were male, 26 were female. Thirty-two had non-functioning adenomas (average diameter 2.5 ± 1.3 cm), and 14 had hormone-secreting tumors (average diameter 2.4 ± 0.7 cm). The most common presenting symptoms were visual loss (42%), endocrinopathy (29%), and headache (16%).

Among patients with non-functioning tumors, tumor resection was complete in 18. One-hundred percent of these patients had no evidence of tumor recurrence 3 years after surgery. More than 5 years of follow-up was available for 10 of these patients (average 8 ± 1.6 years). No tumor recurred over this time period. In contrast, only 8/12 (66%) patients with subtotal resections and no additional treatment remained progression-free at 3 years. This was significantly less than patients with complete resections (X2 = 4.28, p = 0.04). Four patients with subtotal resection and stable imaging at 3 years were followed more than five years (average ± 2 years). Two of these demonstrated progression, and two did not.

Among the 13 patients with functioning tumors, only 4 (26%) had complete resections. All 4 had greater than 5 years of follow-up demonstrating no radiographic recurrence. In contrast, of 7 patients with subtotal resections and no additional treatment, 5 (66%) demonstrated stable tumor size at 3 years after surgery. Four of these patients had greater than 5 years of imaging follow-up (average 8.5 ± 2 years), and all demonstrated stability of their lesions.

Conclusions: These preliminary results suggest that patients with completely resected pituitary lesions are at a low risk of progression and surveillance imaging may safely be widely spaced. In contrast, those with subtotal resections require more frequent surveillance imaging.

 

MissingLinkText

No conflict of interest has been declared by the author(s).